Cash, cash equivalents, and short-term investments were $166.2 million as of March 31, 2024. Based on its current plans, the Company anticipates its cash, cash equivalents, and short-term investments as of March 31, 2024, will enable the Company to fund cash flow requirements into Q4 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
- Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Inozyme reports inducement grants under Nasdaq listing rule
- Inozyme management to meet with Piper Sandler
- Inozyme price target lowered to $14 from $16 at BofA